Compare LTRX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTRX | TLSI |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | United States | United States |
| Employees | N/A | 110 |
| Industry | Computer Communications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.4M | 272.3M |
| IPO Year | 2000 | N/A |
| Metric | LTRX | TLSI |
|---|---|---|
| Price | $6.05 | $5.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $6.50 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.4M | 144.7K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $122,923,000.00 | N/A |
| Revenue This Year | $1.12 | $55.47 |
| Revenue Next Year | $15.27 | $40.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.91 | $3.42 |
| 52 Week High | $8.24 | $7.95 |
| Indicator | LTRX | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 51.92 |
| Support Level | $6.05 | $4.90 |
| Resistance Level | $6.75 | $5.61 |
| Average True Range (ATR) | 0.44 | 0.33 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 61.23 | 73.95 |
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.